GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.
GE HealthCare launched Flyrcado™ (flurpiridaz F 18) at the recent American College of Cardiology (ACC) conference. A positron emission tomography myocardial perfusion imaging (PET MPI) agent for coronary artery disease (CAD) detection, Flyrcado offers ready to use unit dosing and a half-life that is reportedly 10 times higher than that of other cardiac positron emission tomography (PET) agents.
In research presented at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, Flyrcado demonstrated higher sensitivity and specificity rates than single photon emission computed tomography (SPECT) imaging for the detection of CAD in patients with high body mass index (BMI).
Offering ready to use unit dosing and a half-life that is reportedly 10 times higher than that of other cardiac positron emission tomography (PET) agents, the positron emission tomography myocardial perfusion imaging (PET MPI) agent Flyrcado™ will be launched at the American College of Cardiology (ACC) conference. (Image courtesy of GE HealthCare.)
Approved by the FDA in 2024, Flyrcado may facilitate enhanced assessment of ischemia through a combination of exercise stress testing and cardiac PET imaging, according to GE HealthCare, the manufacturer of Flyrcado.
“The launch of Flyrcado represents a significant advancement in cardiac care, providing a new, highly effective diagnostic tool for those with known or suspected coronary artery disease,” said Eric Ruedinger, the vice president and general manager of GE HealthCare’s Pharmaceutical Diagnostics segment for the U.S. and Canada.
The company added that Flyrcado recently garnered pass-through payment status from the Centers for Medicare and Medicaid Services (CMS). GE HealthCare said the pass-through payment status, which goes into effect on April 1, 2025, allows separate reimbursement for the radiopharmaceutical and the PET imaging.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
